Editorial
|
|
|
|
|
It is unacceptable that regulators rely on the drug industry to develop pharmacovigilance
|
|
|
|
New Products
|
|
|
|
|
A vancomycin derivative, no more effective but more toxic
|
|
|
|
|
|
|
|
|
|
Just another injectable cephalosporin
|
|
|
|
|
|
|
|
|
|
No clear advantages when added to chlorambucil
|
|
|
|
|
|
|
|
|
|
|
|
Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Within 90 days after treatment initiation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regress after discontinuation
|
|
|
|
|
|
|
|
|
|
This drug should not be used
|
|
|
|
|
|
|
|
|
|
Dental treatment is a risk factor
|
|
|
|
|
|
|
|
|
|
Mainly reported in non-elective colorectal surgery
|
|
|
|
|
|
|
|
|
|
|
|
Stimulating, euphoriant effects
|
|
|
|
|
|
|
|
|
|
Patients and carers should be informed
|
|
|
|
Reviews
|
|
|
|
|
Similar efficacy to other nicotine delivery devices, but many uncertainties
|
|
|
|
|
|
|
|
|
|
Is cabergoline an alternative to bromocriptine?
|
|
|
|
Outlook
|
|
|
|
|
Action is needed to ensure access to adverse effects
|
|
|
|
|
|
|
|
|
|
The example of benzodiazepine use
|
|
|
|
|
|